IVM
PRTK

InterWest Venture Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

InterWest Venture Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-512,366
Closed -$12.3M – 12
2017
Q2 		$12.3M Hold
512,366
– – 2.92% 6
2017
Q1 		$9.86M Hold
512,366
– – 2.1% 8
2016
Q4 		$7.89M Buy
+512,366
New +$6.65M 1.88% 8

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

InterWest Venture Management's PRTK Position: Q3 2017 in Review

InterWest Venture Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 512,366 shares — an estimated $12.3M sold.

InterWest Venture Management first reported a position in PRTK in Q4 2016 and held it in 3 quarters. The position peaked at $12.3M in Q2 2017. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • InterWest Venture Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • InterWest Venture Management sold 512,366 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $12.3M.
  • InterWest Venture Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 3 quarters.
  • InterWest Venture Management's Paratek Pharmaceuticals, Inc. position peaked at $12.3M in Q2 2017.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on InterWest Venture Management's 13F filing for Q3 2017, filed 11 Oct 2017.